Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
Findings May Potentially Lead to New Approach to Stroke Treatment
BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatmen...
Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets
NEW YORK, July 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson's disease.
Target validation is an essentia...
Dry Mouth Linked to Prescription and Over the Counter Drugs
BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and ...
MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease
NEW YORK, June 25 /PRNewswire-USNewswire/ -- As of mid-2009, The Michael J. Fox Foundation for Parkinson's Research has already funded over
$1 million in high-risk, high-reward approaches to Parkinson's therapeutic development through its groundbreaking Rapid Response Innovation Awards . Projects...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Improvements in Systolic Blood Pressure and Triglycerides Also Observed
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...
PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over
the last five years, which have involved over
PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
- Company Reports Significant Uptake of PlasmaBlade by U.S. Surgeons Since Product Launch -
PALO ALTO, Calif., April 7 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced today several mil...
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presen...
First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008
PARIS, March 24 /PRNewswire-FirstCall/ -- The AXA Research Fund closed out its first year of existence. During the year ended, the Fund granted more than Euro 13 million to various European research institutions.
The purpose of the Fund is to promote the understanding and prevention of major ...
Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy...
The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
DOYLESTOWN, Pa., Feb. 24 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY ) www.quigleyco.com , today announced that it has signed a license with assignment of ownership agreement for its patented formulation QR-340 developed by its wholly owned subsidiary, Quigley Pharma Inc. T...
Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
FirstVue(TM) HBSAG Test Found to Have Higher Sensitivity and Specificity
than Other Rapid HBSAG Tests and FirstVue(TM) '...and was the preferred test in all phases of this evaluation'
CORAL SPRINGS, Fla., Oct. 13 /PRNewswire/ -- AT First Diagnostic LLC an
emerging worldwide m...
Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
Results of FLEXX Trial Presented at the Osteoarthritis Research Society
International's 2008 World Congress
PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc.
recently presented results from the FLEXX Trial of Osteoarthritis of the
Knee, showing that EUFLEXXA(R) (1% sodium...
Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
Results published in New England Journal of Medicine reaffirm
well-established efficacy and long-term safety profile of SPIRIVA(R)
RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNewswire/ -- Results of the
UPLIFT (Understanding Potential Long-term Impacts on Function with
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and
Selexis SA announced today a new milestone in CHO based monoclonal antibody
production with the achievement of manufacturing yields of over
per liter. This record level was accomplished by applying two highly
Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi
Pasteur, the vaccines division of sanofi-aventis Group, announced today its
commitment to donate 60 million doses of H5N1 vaccine to the World Health
Organization (WHO) over
3 years for the establishment of an H5N1 vaccine
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- A head-to-head study
announced today at the American Diabetes Association (ADA) meeting
demonstrated that Levemir(R) (insulin detemir [rDNA origin] injection) can
be used once-daily and had a comparable blood glucose response to insulin
Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
-- Clinical trial data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution presented at International ATS Conference --
NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the
International Conference of the American Thoracic Society (ATS) demonstrate
that concomitant ...
Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
SAN DIEGO, May 19 /PRNewswire/ -- DDW 2008 Annual Meeting -- Ethicon
Endo-Surgery announced today that the results from its pivotal trial
demonstrated physician/nurse teams using the SEDASYS(TM) System reduced the
risk of over
sedation with propofol in patients undergoing screening and
Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting -
SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ --
Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients
treated with the investigatio...
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one
of the world's leading research and adv...
DermaGen AB Receives Over 1 Million Euros From a New Share Issue
LUND, Sweden, April 2 /PRNewswire/ -- DermaGen AB today announced a
cash injection from Midroc New Technology AB who now joins existing owners,
Karolinska Development and Ostersjostiftelsen. The capital will be used for
the further development of DermaGen's first candidate drug. The majority
New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
BRIDGEWATER, N.J., March 15 /PRNewswire-FirstCall/ -- Data presented at
the annual meeting of the American Academy of Allergy Asthma & Immunology
(AAAAI) suggests that the continuous use of intranasal corticosteroid
Nasacort AQ (triamcinolone acetonide) Nasal Spray had no treatment effect
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Following FDA Approval, Company Announces $7,800 Wholesale Price for Lifesaving Drug
LOS ANGELES, Jan. 21 /PRNewswire-USNewswire/ -- AIDS Healthcare
Foundation (AHF) today urged Tibotec Pharmaceuticals Ltd., a division of
Johnson & Johnson, to reconsider and reduce...
AHF Seeks White House Clarification After Press Room Flap Over CDC's HIV Numbers
LOS ANGELES, Dec. 11 /PRNewswire-USNewswire/ -- AIDS Healthcare
Foundation (AHF) is seeking clarification from the White House regarding a
press briefing late last week during which Deputy Press Secretary Dana
Perino had a curt exchange with reporter Les Kingsolving over
tried to ...
Leukemia Drug Proves Safe and Effective Over the Long Term
WASHINGTON, Nov. 7, /PRNewswire-USNewswire/ -- The drug imatinib
mesylate, more commonly known as Gleevec(R), proves safe and effective over
the long term in patients with an advanced form of chronic myeloid leukemia
(CML), according to a study prepublished online in Blood, the official
ACC Concerned Over Reporting of Biomonitoring Results
ARLINGTON, Va., Oct. 23 /PRNewswire-USNewswire/ -- Last evening CNN and
the Discovery Channel aired the documentary, Planet in Peril. The
documentary touched on many environmental and resource issues around the
globe. The American Chemistry Council (ACC) supports efforts like this that
Facet Solutions' AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
LOGAN, Utah, Oct. 22 /PRNewswire/ -- Facet Solutions, Inc. announced
today that testing conducted by Professor Vijay Goel, PhD., from the
Department of Bioengineering at the University of Toledo, demonstrated that
the Anatomic Facet Replacement System (AFRS(TM)) has shown biomechanical
Veto of California's Condoms in Prisons Bill: "Politics Over Public Health," Says AHF
AB 1334, (Swanson, D, Oakland), Sponsored by AIDS Healthcare Foundation
(AHF), AIDS Project Los Angeles (APLA), and the Southern California
HIV/AIDS Coalition (SCHAC) Could Have Helped Reduce Spread of HIV and Other
STDs Among California Inmates
Governor Instructs Department of Corrections to...
CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores
Annual Vaccination Program Begins October 1, 2007
WOONSOCKET, R.I., Sept. 19 /PRNewswire-FirstCall/ -- CVS/pharmacy today
announced that it will help keep America healthy this winter by offering
flu vaccinations in over
4,000 of its stores across the country. The flu
shot clinics wi...
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline
(NYSE: GSK ) today announced new results from a large study that demonstrate
combination treatment with AVODART (dutasteride) and the alpha blocker
tamsulosin provides significantly greater urinary symptom improvement for
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
CAIRNS, Australia, Aug. 31 /PRNewswire/ -- What and When Data from a six-month study of ramelteon will be presented in poster
format at worldsleep07: The 5th World Congress of the World Federation of
Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia
September 2-6, 2...
You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report
BOSTON, Aug. 9 /PRNewswire-USNewswire/ -- Doctors often mistake the
symptoms of thyroid disease for another disorder such as heart failure,
high cholesterol, or even dementia, says a new edition of a report from
Harvard Medical School. The symptoms of thyroid diseases are so
GenoMed Prevents Sickle Cell Pain for Over a Year
ST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC Pink
Sheets:GMED), the Next Generation Disease Management company whose
business is public health(TM), announced today publication of a
case report of a sickle cell patient whose pain has disappeared for
over a year thanks to GenoMed's treatme...
The Lancet Publishes PREVAIL Study Results Showing Lovenox
Superiority Over Unfractionated Heparin for Reducing the Risk of
Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by a
Significant 43% in Acute Ischemic Stroke Patients Treated With
Clexane(R) / Lovenox(R)
BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --
Sanofi-aventis announced the publication of the PREVAIL (Prevention
of VTE after Acute Is...
Doctors Outraged Over Growth Hormone Controversy
Two anti-aging preventative medicine doctors say they are outraged
over recent media coverage about their advocacy of prescribing
human growth hormone to treat a hormone deficiency often associated
DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adult
use of human growth hormon...
Copaxone Treatment over Two Years after Short Term Induction with
Mitoxantrone Provided Sustained Benefits to Active
Relapsing-Remitting Multiple Sclerosis Patients
KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have
demonstrated that relapsing-remitting multiple sclerosis (RRMS)
patients treated with COPAXONE(R) (glatiramer acetate injection)
following brief immunosuppression with mitoxantrone experienced a
90 percent reduction in magnetic resonanc...
Adding Thalidomide to Standard Therapy Improves Survival in Newly
Diagnosed Multiple Myeloma Patients Over Age 75
Phase III Clinical Data on Thalidomide in Multiple Myeloma
Presented at the American Society of Clinical Oncology 43rd Annual
CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion
Corporation today reported the final results of a Phase III study
demonstrating that the addition of Thali...
Study Shows Advantages of Complete Phase Ib Trial Over Separate
Phase I Trials
HOUSTON, June 04, 2007 /PRNewswire/ -- A nationally renowned
cancer researcher affiliated with the US Oncology Research Network
presented a novel study design concept called a Complete Phase Ib
clinical trial as a method to accelerate new agent development.
Studies utilizing this design are curren...